Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative IMRT with concurrent anlotinib for extremity or trunk soft tissue sarcoma
ChiCTR2000033377Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in soft tissue sarcoma (STS), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Major wound complications. Started Jun 2020; status: recruiting.
02
Drugs
anlotinib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2000033377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033377.